The role of oxytocin and vasopressin dysfunction in cognitive impairment and mental disorders

Neuropeptides ◽  
2020 ◽  
Vol 83 ◽  
pp. 102079
Author(s):  
Olga Abramova ◽  
Yana Zorkina ◽  
Valeria Ushakova ◽  
Eugene Zubkov ◽  
Anna Morozova ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mental Disorders

scholarly journals Mental disorders and cognitive impairment in patients with antiphospholipid syndrome

2020 ◽  
Vol 92 (5) ◽  
pp. 92-103
Author(s):  
A. B. Borisova ◽  
T. A. Lisitsyna ◽  
D. Yu. Veltishchev ◽  
T. M. Reshetnyak ◽  
O. F. Seravina ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mental Disorders ◽  
Antiphospholipid Syndrome ◽  
Depressive Disorders ◽  
Stress Factors ◽  
Model Of Care ◽  
Partnership Model ◽  
The Relationship

Mental disorders (mainly anxiety and depressive disorders) and cognitive impairment are often found in patients with antiphospholipid syndrome (APS), but their prevalence, structure, and mechanisms of occurrence are not well researched. The review provides literature data on the frequency, spectrum and possible causes of mental disorders and cognitive impairment in patients with APS, the pathogenetic mechanisms of these disorders (in particular, the important role of antiphospholipid antibodies, stress factors, chronic inflammation), the relationship between APS, mental disorders and as well as cognitive impairment is examined. Special attention is paid to the influence of mental disorders and cognitive impairment on patients adherence to treatment, their quality of life, as well as the particularities of psychopharmacotherapy of mental disorders in patients with APS. The aim of the review is to actualize the interdisciplinary problem of mental disorders and cognitive impairment in patients with APS and the need to introduce a partnership model of care.

scholarly journals Mental Illness and Amyloid: A Scoping Review of Scientific Evidence over the Last 10 Years (2011 to 2021)

2021 ◽  
Vol 11 (10) ◽  
pp. 1352
Author(s):  
Gianluca Pandolfo ◽  
Fiammetta Iannuzzo ◽  
Giovanni Genovese ◽  
Antonio Bruno ◽  
Giovanni Pioggia ◽  
...  
Keyword(s):  
Mental Illness ◽  
Cognitive Impairment ◽  
Mental Disorders ◽  
Psychiatric Patients ◽  
Scientific Evidence ◽  
Mental Illnesses ◽  
Tau Proteins ◽  
Amyloid A ◽  
Amyloid Metabolism

Amyloid precursor protein and its derivates represent a central factor in the process of neurodegeneration in Alzheimer’s disease (AD). Since mental illnesses share with AD cognitive impairment, amyloid indicators have been used to explore the unknown pathophysiologic mechanisms underlining psychiatric illness. This work aims to compare the role of amyloid markers, together with tau proteins, among various mental disorders evaluating the possible role of altered amyloid metabolism in the onset and in the course of psychiatric diseases, considering the relationship with cognitive impairment in dementia. This review includes articles written in English, published between 1 January 2011 and 31 January 2021, which evaluated amyloid and tau proteins in psychiatric patients. After screening, 31 studies were included in the review. Results suggest that amyloid metabolism is altered in major psychiatric disorders and that it could be a marker of cognitive impairment. Nevertheless, the role of amyloid in mental diseases seems to be related to neurodevelopmental alteration as well as neurodegeneration processes, like in AD. The role of amyloid in the pathogenesis of mental disorders is still unknown. Amyloid should not be only considered as a marker of cognitive impairment in mental illness, but also for altered neurodevelopment.

The role of tau-protein in the diagnosis of cognitive impairment in diabetes

2020 ◽  
Author(s):  
Mariia Matveeva ◽  
Julia Samoilova ◽  
Natalie Zhukova
Keyword(s):  
Cognitive Impairment ◽  
Tau Protein

The Role of Cardiovascular Disease in Cognitive Impairment

2020 ◽  
Vol 9 (1) ◽  
pp. 1-9
Author(s):  
Michelle C. Johansen ◽  
Nicole Langton-Frost ◽  
Rebecca F. Gottesman
Keyword(s):  
Cardiovascular Disease ◽  
Cognitive Impairment

scholarly journals Dysregulation of Astrocyte–Neuronal Communication in Alzheimer’s Disease

2021 ◽  
Vol 22 (15) ◽  
pp. 7887
Author(s):  
Carmen Nanclares ◽  
Andres Mateo Baraibar ◽  
Alfonso Araque ◽  
Paulo Kofuji
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Synaptic Plasticity ◽  
Neuronal Excitability ◽  
Active Role ◽  
Ionic Homeostasis ◽  
Neuronal Communication ◽  
Structural Support

Recent studies implicate astrocytes in Alzheimer’s disease (AD); however, their role in pathogenesis is poorly understood. Astrocytes have well-established functions in supportive functions such as extracellular ionic homeostasis, structural support, and neurovascular coupling. However, emerging research on astrocytic function in the healthy brain also indicates their role in regulating synaptic plasticity and neuronal excitability via the release of neuroactive substances named gliotransmitters. Here, we review how this “active” role of astrocytes at synapses could contribute to synaptic and neuronal network dysfunction and cognitive impairment in AD.

Sign in / Sign up

Export Citation Format

Share Document